Study of tumor infiltrating lymphocytes and transforming growth factor-β as prognostic factors in breast carcinoma
Open Access
- 21 October 1997
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 74 (5), 492-501
- https://doi.org/10.1002/(sici)1097-0215(19971021)74:5<492::aid-ijc3>3.0.co;2-z
Abstract
Cytokines and growth factors are powerful modulators of the immune response. Their aberrant expression either by the tumor cells or by the tumor infiltrating lymphocytes confers a selective advantage to the tumor to grow and suppress the cytotoxic activity of the infiltrating lymphocytes. Therefore, analysis of these soluble factors in the tumor microenvironment can provide an insight into the understanding of the tumor behavior and may be used as a prognostic factor. In the present study the nature of the tumor infiltrating lymphocytes (TILs) and cytokine profile was examined in 36 and 19 mammary carcinoma tissues, respectively, by immunohistochemistry and PCR. Phenotypic differences in the number of cytotoxic T lymphocytes (CD8+) and lymphokine activated killer cells (CD16) was observed among TILs when patients with either early disease stage (39% and 46.6%, respectively) or those alive with no residual disease (31% and 52%, respectively) were compared with late stage (9.7% and 22.8%, respectively) or those dead of disease (14.6% and 15.6%, respectively). Furthermore, analysis of the 19 tumor samples for cytokine mRNA expression by RT-PCR revealed the presence of TNF-α, IL-10, TGF-β1, and IL-2. However, semi-quantitative PCR analysis demonstrated TGF- β1 expression to be significantly higher in patients with a favorable outcome (1.0246 attomoles/μmoles) as compared to patients with a poor prognosis (0.1157 attomoles/μmoles). Our results demonstrate the potential biological significance of certain host factors, particularly TILs and TGF β1 expression, on the outcome of breast cancer. Int. J. Cancer 74:492–501, 1997.Keywords
This publication has 20 references indexed in Scilit:
- Tumour‐associated leucocytes: Friends or foes in breast carcinomaThe Journal of Pathology, 1994
- Changing trends: An overview of breast cancer incidence and mortalityCancer, 1994
- In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53European Journal of Immunology, 1993
- Modulation of Macrophage Function by Transforming Growth Factor β, Interleukin‐4, and Interleukin‐10aAnnals of the New York Academy of Sciences, 1993
- Interleukin-10Annual Review of Immunology, 1993
- CD16 on human γδ T lymphocytes: Expression, function, and specificity for mouse IgG isotypesCellular Immunology, 1992
- Inhibition of DNA synthesis by TGF-β1 coincides with inhibition of phosphorylation and cytoplasmic translocation of p53 proteinBiochemical and Biophysical Research Communications, 1992
- Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4Science, 1991
- Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.The Journal of Experimental Medicine, 1983
- Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.Journal of Histochemistry & Cytochemistry, 1981